trial_id,sentence_id,sentence,inclusion,ent_text,ent_type
1,1,Patients diagnosed with type 2 diabetes mellitus ,1,type 2 diabetes mellitus,PROBLEM
1,2,Patients have treated with diet/exercise at least 3 months ,1,,
1,3,"7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after run-in ",1,HbA1C,TEST
1,3,"7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after run-in ",1,screening,TEST
1,3,"7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after run-in ",1,HbA1C,TEST
1,4,Patient has history of type 1 diabetes mellitus ,0,type 1 diabetes mellitus,PROBLEM
1,5,Patient has history of ketoacidosis ,0,ketoacidosis,PROBLEM
1,6,Patient has history of severe unconscious hypoglycemosis ,0,severe unconscious hypoglycemosis,PROBLEM
1,7,Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis ,0,acute and chronic pancreatitis,PROBLEM
1,7,Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis ,0,pancreatic injury,PROBLEM
1,7,Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis ,0,pancreatitis,PROBLEM
1,8,"Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical ",0,decompensated heart failure,PROBLEM
1,8,"Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical ",0,unstable angina,PROBLEM
1,8,"Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical ",0,stroke,PROBLEM
1,8,"Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical ",0,transient ischemic attack,PROBLEM
1,8,"Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical ",0,myocardial infarction,PROBLEM
1,9,"Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg ",0,hypertension,PROBLEM
1,9,"Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg ",0,antihypertensive treatment,TREATMENT
1,9,"Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg ",0,systolic blood pressure,TEST
1,9,"Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg ",0,diastolic blood pressure,TEST
1,10,"Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL)；total bilirubin >2×UNL； creatinine>1.5 mg/dL (Male,132.6μmol/L) ，>1.4 mg/dL(Female，123.8μmol/L) ",0,severe liver,PROBLEM
1,10,"Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL)；total bilirubin >2×UNL； creatinine>1.5 mg/dL (Male,132.6μmol/L) ，>1.4 mg/dL(Female，123.8μmol/L) ",0,kidney disease,PROBLEM
1,10,"Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL)；total bilirubin >2×UNL； creatinine>1.5 mg/dL (Male,132.6μmol/L) ，>1.4 mg/dL(Female，123.8μmol/L) ",0,alanine aminotransferase,TEST
1,10,"Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL)；total bilirubin >2×UNL； creatinine>1.5 mg/dL (Male,132.6μmol/L) ，>1.4 mg/dL(Female，123.8μmol/L) ",0,Aspartate Aminotransferase,TEST
1,10,"Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL)；total bilirubin >2×UNL； creatinine>1.5 mg/dL (Male,132.6μmol/L) ，>1.4 mg/dL(Female，123.8μmol/L) ",0,；total bilirubin,TEST
1,10,"Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL)；total bilirubin >2×UNL； creatinine>1.5 mg/dL (Male,132.6μmol/L) ，>1.4 mg/dL(Female，123.8μmol/L) ",0,creatinine,TEST
1,10,"Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL)；total bilirubin >2×UNL； creatinine>1.5 mg/dL (Male,132.6μmol/L) ，>1.4 mg/dL(Female，123.8μmol/L) ",0,"Male,132.6μmol",TEST
1,11,"Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery ",0,severe chronic gastrointestinal disease,PROBLEM
1,11,"Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery ",0,therapy,TREATMENT
1,11,"Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery ",0,drug absorption,PROBLEM
1,11,"Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery ",0,gastrointestinal surgery,TREATMENT
1,12,Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. ) ,0,severe haematological diseases,PROBLEM
1,12,Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. ) ,0,other diseases,PROBLEM
1,12,Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. ) ,0,hemolyze,TEST
1,12,Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. ) ,0,red blood cell unstable (malaria、haemolytic anaemia eg.,PROBLEM
1,13,"Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on ",0,other endocrine diseases,PROBLEM
1,13,"Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on ",0,example hyperthyroidism,PROBLEM
1,13,"Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on ",0,、hypothyroidism,PROBLEM
1,13,"Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on ",0,、hypercortisolism,PROBLEM
1,13,"Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on ",0,、multiple endocrine neoplasia,PROBLEM
1,14,Patient has history of malignancy ,0,malignancy,PROBLEM
1,15,Patient has history of alcohol or drug abuse,0,,
2,16,"males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on diet only ",1,T2DM,PROBLEM
2,16,"males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on diet only ",1,HbA1c,TEST
2,16,"males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on diet only ",1,≥,TEST
2,16,"males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on diet only ",1,≤,TEST
2,17,take stable doses of oral antihyperglycemic agents with or without long-acting insulin ,1,oral antihyperglycemic agents,TREATMENT
2,17,take stable doses of oral antihyperglycemic agents with or without long-acting insulin ,1,long-acting insulin,TREATMENT
2,18,must have a regular primary care provider (PCP) that is amenable to patient study participation and will facilitate (blinded to the treatment) the research team's study protocol efforts ,1,,
2,19,type 1 diabetes mellitus (T1DM) ,0,type 1 diabetes mellitus (T1DM),PROBLEM
2,20,current or recent glucagon-like peptide 1 receptor (GLP-1R) agonist use ,0,recent glucagon-like peptide,TREATMENT
2,21,"contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus inappropriate for MRI exam) ",0,MRI,TEST
2,21,"contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus inappropriate for MRI exam) ",0,claustrophobia,PROBLEM
2,21,"contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus inappropriate for MRI exam) ",0,body habitus,TEST
2,21,"contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus inappropriate for MRI exam) ",0,MRI exam,TEST
2,22,"screening carotid ultrasound plaque thickness of <0.75 mm, prior or anticipated carotid stenting or endarterectomy ",0,screening carotid ultrasound plaque thickness,TEST
2,22,"screening carotid ultrasound plaque thickness of <0.75 mm, prior or anticipated carotid stenting or endarterectomy ",0,anticipated carotid stenting,TREATMENT
2,22,"screening carotid ultrasound plaque thickness of <0.75 mm, prior or anticipated carotid stenting or endarterectomy ",0,endarterectomy,TREATMENT
2,23,"recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g., pancreatitis, severe renal disease) or personal or family history of medullary thyroid carcinoma ",0,recent CVD,PROBLEM
2,23,"recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g., pancreatitis, severe renal disease) or personal or family history of medullary thyroid carcinoma ",0,other major illness,PROBLEM
2,23,"recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g., pancreatitis, severe renal disease) or personal or family history of medullary thyroid carcinoma ",0,pancreatitis,PROBLEM
2,23,"recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g., pancreatitis, severe renal disease) or personal or family history of medullary thyroid carcinoma ",0,severe renal disease,PROBLEM
2,23,"recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g., pancreatitis, severe renal disease) or personal or family history of medullary thyroid carcinoma ",0,medullary thyroid carcinoma,PROBLEM
2,24,patients with Multiple Endocrine Neoplasia syndrome type 2 ,0,Multiple Endocrine Neoplasia syndrome type 2,PROBLEM
2,25,serious hypersensitivity to exenatide or any product components ,0,serious hypersensitivity,PROBLEM
2,25,serious hypersensitivity to exenatide or any product components ,0,exenatide,TREATMENT
2,25,serious hypersensitivity to exenatide or any product components ,0,any product components,PROBLEM
2,26,"severe gastrointestinal disease, or pregnancy",0,severe gastrointestinal disease,PROBLEM
2,26,"severe gastrointestinal disease, or pregnancy",0,pregnancy,PROBLEM
3,27,Participants with a diagnosis of type 2 diabetes mellitus (T2DM) ,1,type 2 diabetes mellitus,PROBLEM
3,27,Participants with a diagnosis of type 2 diabetes mellitus (T2DM) ,1,T2DM,PROBLEM
3,28,Random C-peptide at screening greater than (>)0.6 nanogram/milliliter (ng/mL) (>0.2 nanomole/liter [nmol]/L]) ,1,Random C-peptide at screening,TEST
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,HbA1c,TEST
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,screening,TEST
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,exercise,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,metformin monotherapy,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,screening,TEST
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,exercise,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,a stable insulin monotherapy regimen,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,screening,TEST
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,the insulin regimen,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,insulin,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,the total daily dose of insulin,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,exercise,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,a stable combination therapy,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,metformin,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,insulin,TREATMENT
3,29,"HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below: 1. On diet and exercise only for at least 4 weeks prior to screening 2. On diet and exercise and a stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening 3. On diet and exercise and a stable insulin monotherapy regimen for at least 8 weeks prior to screening (stable dose is defined as no change in the insulin regimen [ie, type{s} of insulin] and <=15% change in the total daily dose of insulin [averaged over 1 week to account for day to day variability]) 4. On diet and exercise and a stable combination therapy with metformin and insulin for at least 8 weeks prior to screening ",1,screening,TEST
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,diabetic ketoacidosis,PROBLEM
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,DKA,PROBLEM
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,type 1 diabetes mellitus,PROBLEM
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,T1DM),PROBLEM
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,pancreas or cell transplantation,TREATMENT
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,diabetes,PROBLEM
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,pancreatitis,PROBLEM
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,pancreatectomy,TREATMENT
3,30,"History of diabetic ketoacidosis (DKA), type 1 diabetes mellitus (T1DM), pancreas or cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy or maturity onset diabetes of the young (MODY) ",0,maturity onset diabetes of the young (MODY),PROBLEM
3,31,"Participants on any antihyperglycemic agents (AHAs) other than metformin, or injectable insulin within 8 weeks of the first dose of study drug (that is Day 1) ",0,any antihyperglycemic agents,TREATMENT
3,31,"Participants on any antihyperglycemic agents (AHAs) other than metformin, or injectable insulin within 8 weeks of the first dose of study drug (that is Day 1) ",0,metformin,TREATMENT
3,31,"Participants on any antihyperglycemic agents (AHAs) other than metformin, or injectable insulin within 8 weeks of the first dose of study drug (that is Day 1) ",0,injectable insulin,TREATMENT
3,31,"Participants on any antihyperglycemic agents (AHAs) other than metformin, or injectable insulin within 8 weeks of the first dose of study drug (that is Day 1) ",0,study drug,TREATMENT
3,32,"Repeated (2 or more over a 1-week period) fasting self-monitoring of blood glucose (SMBG) measurements >270 milligram/deciliter (mg/dL) (>15 millimole/liter [mmol/L]) during the pretreatment phase, despite reinforcement of diet and exercise counseling ",0,blood glucose,TEST
3,32,"Repeated (2 or more over a 1-week period) fasting self-monitoring of blood glucose (SMBG) measurements >270 milligram/deciliter (mg/dL) (>15 millimole/liter [mmol/L]) during the pretreatment phase, despite reinforcement of diet and exercise counseling ",0,SMBG,TEST
3,32,"Repeated (2 or more over a 1-week period) fasting self-monitoring of blood glucose (SMBG) measurements >270 milligram/deciliter (mg/dL) (>15 millimole/liter [mmol/L]) during the pretreatment phase, despite reinforcement of diet and exercise counseling ",0,the pretreatment phase,TREATMENT
3,32,"Repeated (2 or more over a 1-week period) fasting self-monitoring of blood glucose (SMBG) measurements >270 milligram/deciliter (mg/dL) (>15 millimole/liter [mmol/L]) during the pretreatment phase, despite reinforcement of diet and exercise counseling ",0,exercise counseling,TREATMENT
3,33,Severe hypoglycemia within 6 months prior to Day 1 ,0,Severe hypoglycemia,PROBLEM
3,34,History of hereditary glucose-galactose malabsorption or primary renal glucosuria ,0,hereditary glucose-galactose malabsorption,PROBLEM
3,34,History of hereditary glucose-galactose malabsorption or primary renal glucosuria ,0,primary renal glucosuria,PROBLEM
3,35,"Alanine aminotransferase level >5.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN at screening (for elevations in bilirubin: if, in the opinion of the investigator and agreed upon by the sponsor's medical officer, the elevation in bilirubin is consistent with Gilbert's disease, the subject may participate)",0,Alanine aminotransferase level,TEST
3,35,"Alanine aminotransferase level >5.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN at screening (for elevations in bilirubin: if, in the opinion of the investigator and agreed upon by the sponsor's medical officer, the elevation in bilirubin is consistent with Gilbert's disease, the subject may participate)",0,ULN,TEST
3,35,"Alanine aminotransferase level >5.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN at screening (for elevations in bilirubin: if, in the opinion of the investigator and agreed upon by the sponsor's medical officer, the elevation in bilirubin is consistent with Gilbert's disease, the subject may participate)",0,total bilirubin,TEST
3,35,"Alanine aminotransferase level >5.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN at screening (for elevations in bilirubin: if, in the opinion of the investigator and agreed upon by the sponsor's medical officer, the elevation in bilirubin is consistent with Gilbert's disease, the subject may participate)",0,the ULN at screening,TEST
3,35,"Alanine aminotransferase level >5.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN at screening (for elevations in bilirubin: if, in the opinion of the investigator and agreed upon by the sponsor's medical officer, the elevation in bilirubin is consistent with Gilbert's disease, the subject may participate)",0,elevations in bilirubin,PROBLEM
3,35,"Alanine aminotransferase level >5.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN at screening (for elevations in bilirubin: if, in the opinion of the investigator and agreed upon by the sponsor's medical officer, the elevation in bilirubin is consistent with Gilbert's disease, the subject may participate)",0,the elevation in bilirubin,PROBLEM
3,35,"Alanine aminotransferase level >5.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN at screening (for elevations in bilirubin: if, in the opinion of the investigator and agreed upon by the sponsor's medical officer, the elevation in bilirubin is consistent with Gilbert's disease, the subject may participate)",0,Gilbert's disease,PROBLEM
4,36,"Male or female, aged between 18 and 72 years (both inclusive) at the time of signing informed consent. ",1,,
4,37,Body mass index between 18.5 and 37.9 kg/m^2 (both inclusive). ,1,Body mass index,TEST
4,38,Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening. ,1,type 2 diabetes mellitus,PROBLEM
4,38,Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening. ,1,screening,TEST
4,39,Glycosylated haemoglobin type A1c (HbA1c) less than or equal to 9.0% (less than or equal to 74 mmol/mol) at screening. ,1,Glycosylated haemoglobin type A1c,TEST
4,39,Glycosylated haemoglobin type A1c (HbA1c) less than or equal to 9.0% (less than or equal to 74 mmol/mol) at screening. ,1,HbA1c,TEST
4,39,Glycosylated haemoglobin type A1c (HbA1c) less than or equal to 9.0% (less than or equal to 74 mmol/mol) at screening. ,1,screening,TEST
4,40,Current total daily insulin treatment between 0.2 and 1.0 U/kg/day (both inclusive). ,1,Current total daily insulin treatment,TREATMENT
4,41,Known or suspected hypersensitivity to trial products or related products. ,0,hypersensitivity,PROBLEM
4,41,Known or suspected hypersensitivity to trial products or related products. ,0,trial products,TREATMENT
4,42,"Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method. ",0,an adequate contraceptive method,TREATMENT
4,43,"Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus).",0,"any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions",PROBLEM
4,43,"Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus).",0,diabetes mellitus,PROBLEM
5,44,"Patients who are participating (or who have participated) in qualifying studies and who have not been required to discontinue study treatment for protocol or safety reasons and who have completed required End-of-Treatment and/or Follow-up visits in a prior clinical study with bardoxolone methyl and who, according to the assessment of the investigator, have a potential positive benefit-risk assessment for participating in the trial. ",1,study treatment,TREATMENT
5,44,"Patients who are participating (or who have participated) in qualifying studies and who have not been required to discontinue study treatment for protocol or safety reasons and who have completed required End-of-Treatment and/or Follow-up visits in a prior clinical study with bardoxolone methyl and who, according to the assessment of the investigator, have a potential positive benefit-risk assessment for participating in the trial. ",1,protocol,TREATMENT
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,assessments,TEST
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,the prior qualifying study,TEST
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,end stage kidney disease,PROBLEM
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,ESKD),PROBLEM
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,nephrotic syndrome,PROBLEM
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,study enrollment,TEST
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,eGFR,TEST
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,eGFR decline,PROBLEM
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,eligibility assessment,TEST
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,BNP,TEST
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,a cardiovascular serious adverse event,PROBLEM
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,the prior qualifying study,TEST
5,45,"Meets the following eligibility criteria based on assessments from the prior qualifying study (last on-treatment visit) or from a screening visit, if applicable: 1. Not expected to reach end stage kidney disease (ESKD) or nephrotic syndrome within 12 weeks of study enrollment, in the investigator's judgement; subjects with eGFR <20 ml/min/1.73m2 should be discussed with the medical monitor before enrollment (e.g., such subjects with an average rate of eGFR decline > 1.0 ml/min/1.73m2 per month in the 3 months prior to eligibility assessment may not be eligible); 2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study or at a new screening visit, if applicable; 3. No occurrence of a cardiovascular serious adverse event in the prior qualifying study or in the interval between the end of the qualifying study and the screening visit, if applicable. ",1,the qualifying study,TEST
5,46,"Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. ",1,treatment plan,TREATMENT
5,46,"Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. ",1,laboratory tests,TEST
5,46,"Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. ",1,other study procedures,TEST
5,47,Evidence of a personally signed and dated informed consent document (and assent form if necessary) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study prior to initiation of any protocol-mandated procedures. ,1,the study,TEST
5,47,Evidence of a personally signed and dated informed consent document (and assent form if necessary) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study prior to initiation of any protocol-mandated procedures. ,1,any protocol-mandated procedures,TREATMENT
5,48,Participation in other investigational clinical studies involving interventional products being tested or used in a way different from the approved form or when used for an unapproved indication; ,0,investigational clinical studies,TEST
5,48,Participation in other investigational clinical studies involving interventional products being tested or used in a way different from the approved form or when used for an unapproved indication; ,0,interventional products,TREATMENT
5,49,Patients who have an ongoing SAE from a clinical study that is assessed by the investigator as related to bardoxolone methyl; ,0,an ongoing SAE,PROBLEM
5,49,Patients who have an ongoing SAE from a clinical study that is assessed by the investigator as related to bardoxolone methyl; ,0,a clinical study,TEST
5,49,Patients who have an ongoing SAE from a clinical study that is assessed by the investigator as related to bardoxolone methyl; ,0,bardoxolone methyl,TREATMENT
5,50,"Unwilling to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while screening, taking study drug and 30 days after the last study drug dose; ",0,birth control,TREATMENT
5,51,Women who are pregnant or breastfeeding; ,0,,
5,52,"Patient is, in the opinion of the investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason; ",0,the study protocol,TEST
5,52,"Patient is, in the opinion of the investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason; ",0,the study,TEST
5,53,Known hypersensitivity to any component of the study drug.,0,Known hypersensitivity,PROBLEM
